Systemic Lupus Erythematosus - Drug Pipeline Landscape, 2023

Systemic Lupus Erythematosus - Drug Pipeline Landscape, 2023

Systemic lupus erythematosus (SLE) also referred as lupus. It is a chronic, inflammatory autoimmune disease with multiorgan involvement. In this condition, the body attacks its own immune system and causes inflammation as well as tissue damage.

SLE is mainly of three types: 1) Acute cutaneous lupus erythematosus, 2) Chronic cutaneous or discoid lupus erythematosus and 3) Subacute cutaneous lupus erythematosus.

The exact cause of SLE condition is still unknown. Main factors associated with disease development and activity are environmental triggers, genetic predisposition and hormonal milieu interplay.

The common symptoms associated with SLE are inflamed joints, fatigue, fever, mouth ulcers, swollen lymph nodes, hair loss, chest pain, rashes mostly on face and anemia.

The primary diagnosis of SLE can be determined by any of the symptoms and signs. The diagnosis also involves physical examination, blood and urine tests, and skin or kidney biopsy. Other tests that are involved in confirming the severity are antinuclear antibodies (ANA) and anti-double stranded (ds) DNA (anti-dsDNA) test, CBC with differentials, urine analysis and chemistry profile including renal and liver enzymes.

The main goal of the SLE treatment is to avoid known triggering factors, preventing from tissue damage, reducing comorbidities secondary to lupus and addressing fatigue and pain. And the treatment also based on the organs and systems involved as well as the severity. Mild to moderate lupus condition can be treated with NSAIDs, anti-malarial agents and corticosteroids, in severe conditions immunosuppressive agents are included.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of systemic lupus erythematosus treatment such as Mizoribine, Daxdilimab, Mosunetuzumab, and others. Key players involved in the development of therapies to treat systemic lupus erythematosus are Asahi Kasei Pharma Corp, Novartis, AstraZeneca, Genentech, and others. One drug is under Pre-Registration stage, 10+ are in Phase III clinical trials and 40+ drugs are in Phase II clinical trials and some other drugs are under Phase I Phase 0, and preclinical stages of development. In Oct 2022, Biogen Inc announced that it has enrolled first patient in the global clinical study of AMETHYST Phase II/III of litifilimab.

Report Highlights

Global Insight Service's, Systemic Lupus Erythematosus - Drug Pipeline Landscape, 2023 report provides an overview of the Systemic Lupus Erythematosus pipeline drugs. This report covers detailed insights on Systemic Lupus Erythematosus drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Systemic Lupus Erythematosus pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.